Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium trisulfide (Na2S3) is an inorganic polysulfide and sulfane sulfur donor that acts as a fast-releasing hydrogen sulfide (H2S) and hydrogen polysulfide (H2Sn) donor. It is widely utilized as a research tool to investigate the physiological and pharmacological roles of reactive sulfur species (RSS) and supersulfides in cellular signaling and cytoprotection. Preclinical studies have demonstrated that sodium trisulfide exerts protective effects against hepatic ischemia-reperfusion injury (IRI) by mitigating oxidative stress, restoring mitochondrial function, and maintaining the expression of key enzymes in the sulfide oxidation pathway, such as sulfide-quinone oxidoreductase (SQOR). Additionally, it has shown neuroprotective properties in models of dopaminergic neurodegeneration and intracerebral hemorrhage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium trisulfide.